Sarepta Therapeutics
A biopharmaceutical company focused on innovative RNA-based therapeutics
Based in MA
🤖
AI Overview
With $2.5M in lobbying spend across 31 quarterly filings, Sarepta Therapeutics is a significant lobbying presence. They deploy 12 individual lobbyists
$2.5M
Total Lobbying Spend
31
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $320K |
| 2019 | $160K |
| 2020 | $400K |
| 2021 | $240K |
| 2022 | $400K |
| 2023 | $320K |
| 2024 | $240K |
| 2025 | $430K |
Lobbying Firms
TARPLIN, DOWNS & YOUNG, LLC
What They Lobby For
- PL 114-255 - 21st Century Cures, implementation S. 204 - Right to Try Act of 2017 S. 456 - RACE for Children Act S. 771 - Improving Access to Affordable Prescription Drugs Act S. 637 - Creating Transparency to Have Drug Rebates Unlocked Act of 2017 Stopping the Pharmaceutical Industry From Keeping Drugs Expensive Act of 2017 S. 469 - Affordable and Safe Prescription Drug Importation act H.R. 749 - Lower Drug Costs Through Competition Act H.R. 2430 - FDA Reauthorization Act of 2017 no specific bills: Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference
- Medicaid Drug Rebate Program, coverage, state program operations, waivers H.R. 3921 - Healthy Kids Act S. 1827 - Kids Act of 2017
- H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 no specific bill, appropriations
- H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution no specific bill, appropriations
- H.R. 1625 - Consolidated Appropriations Act of 2018 H.R. 1892 - Bipartisan Budget Act of 2018 H.R. 6157 - HHS appropriations and continuing resolution H.R. 695 - Department of Defense Appropriations Act no specific bill, appropriations
- H.J.Res. 31 - Consolidated Appropriations Act, 2019 no specific bill, appropriations
- Medicaid Drug Rebate Program, coverage, state program operations, waivers, gene therapy, value based contracting H.R. 259 - Medicaid Extenders Act of 2019 H.R. 1839 - Medicaid Services Investment and Accountability Act of 2019
- no specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
- S. 1895 - Lower Health Care Costs Act no specific bills, Innovation, Duchenne Muscular Dystrophy, platform technologies, non-interference, transparency, value based contracting, gene therapy
- H.R. 3164 - FDA Appropriations, 2020
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.